What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Carvacrol, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, E-cadherin, p53, and TA-p73/p63, stalls cell cycle progression, inhibits immune-inhibitory receptors/molecules, suppresses cancer stem cell proliferation, inhibits migration, invasion and metastasis of cancer cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene
The Significance of the study to Public health relevance:
First, given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die due to lack of curative treatment available at present; (ii) cancer deaths globally are expected to be doubled by 2030; and (iii) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to prevent an individual from being susceptible to cancer by strengthening his/her own immune system (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (iii) a side-effect-free natural product-based anticancer drugs that target cancer stem cells; and (iv) a way to effectively treat and prevent metastatic progression and relapse of ovarian cancers.
Second, given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.
From research findings to therapeutic opportunity :
(i) Therapeutic strategy:
This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.
(ii) Research findings:
This study suggests, for the first time, that A pharmacological formulation encompassing Carvacrol and probiotic Lactobacillus rhamnosus, by increasing the expression of its target genes, it may: (i) decrease the expression of a number of oncogenes and DNA repair proteins; (ii) increase the expression of tumor/metastasis suppressor genes, such as E-cadherin, TPM1, CADM1/2; (iii) increase the expression of a number of other tumor suppressor genes, including p53/TA-p73/p63, and their target genes, INKa/p19ARF and others (Figure 1);(iv) activate tumor/metastasis suppressor network; (v) inhibit immunosuppressive/immune-inhibitory receptors/ molecules; (vi) inhibit the activity and proliferation of cancer stem cells; (vii) inhibit cell cycle progression & tumor growth; and (viii) promote survival (Figures 1-2).
Further, the efficacy of a number of anti-cancer therapy can be increased by treating cancer patients with a pharmaceutical mixture encompassing Xylobiose and probiotic Lactobacillus rhamnosus (1.0×103 CFU/ml). Thus, a pharmacological formulation encompassing “ Carvacrol or its analogs, either alone or in combination with other known anticancer drugs, or probiotics enriched with anti-cancer activity, such as Lactobacillus rhamnosus,” may be used to inhibit the progression of advanced cancers and promote disease-free survival (Figure 3)
Given the mechanism of action of Carvacrol and its non-toxic nature, compared to other anticancer drugs, it may be an ideal anti-metastatic agent to (i) increase the expression of metastasis/tumor suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors, and (ii) enhance the efficacy of anti-cancer therapy.
Taken together, this study suggests that oncologists may consider treating terminally ill metastatic cancer patients with Carvacrol or putting this interesting observation into a clinical trial, as it may stall the progression of advanced metastatic cancers.
Details of the Research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Amount: $ 500#
Undisclosed mechanistic information: How does Carvacrol increase the expression of tumor/metastatic suppressors E-cadherin, TPM1, CADM1/2, and others?
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at firstname.lastname@example.org
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Natural product-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Carvacrol, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, E-cadherin, p53, and TA-p73/p63, stalls cell cycle progression, inhibits immune-inhibitory receptors/molecules, suppresses cancer stem cell proliferation, inhibits migration, invasion and metastasis of cancer cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 16/May/2019, 10.52 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, Kindly drop us a line at email@example.com